CN111886010A - 用于治疗与etbr激活相关的癌症的氘化化合物、组合物和方法 - Google Patents

用于治疗与etbr激活相关的癌症的氘化化合物、组合物和方法 Download PDF

Info

Publication number
CN111886010A
CN111886010A CN201980018691.9A CN201980018691A CN111886010A CN 111886010 A CN111886010 A CN 111886010A CN 201980018691 A CN201980018691 A CN 201980018691A CN 111886010 A CN111886010 A CN 111886010A
Authority
CN
China
Prior art keywords
optionally substituted
compound
substituted
cancer
heteroaryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980018691.9A
Other languages
English (en)
Chinese (zh)
Inventor
S·贾马尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Enb Therapy
Original Assignee
Enb Therapy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Enb Therapy filed Critical Enb Therapy
Publication of CN111886010A publication Critical patent/CN111886010A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201980018691.9A 2018-01-12 2019-01-11 用于治疗与etbr激活相关的癌症的氘化化合物、组合物和方法 Pending CN111886010A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862616729P 2018-01-12 2018-01-12
US62/616,729 2018-01-12
PCT/US2019/013377 WO2019140324A1 (en) 2018-01-12 2019-01-11 Deuterated compounds, compositions, and methods for treating cancers associated with etbr activation

Publications (1)

Publication Number Publication Date
CN111886010A true CN111886010A (zh) 2020-11-03

Family

ID=67212721

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980018691.9A Pending CN111886010A (zh) 2018-01-12 2019-01-11 用于治疗与etbr激活相关的癌症的氘化化合物、组合物和方法

Country Status (10)

Country Link
US (4) US10435434B2 (https=)
EP (1) EP3713571A4 (https=)
JP (1) JP7539151B2 (https=)
KR (1) KR102846292B1 (https=)
CN (1) CN111886010A (https=)
AU (1) AU2019206652B2 (https=)
CA (1) CA3087009A1 (https=)
EA (1) EA202091630A1 (https=)
MX (1) MX2020007293A (https=)
WO (1) WO2019140324A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10695400B2 (en) 2015-08-03 2020-06-30 Enb Therapeutics, Inc. Compositions and methods for treating cancers associated with ETBR activation
AU2019206652B2 (en) * 2018-01-12 2024-11-14 Enb Therapeutics, Inc. Deuterated compounds, compositions, and methods for treating cancers associated with ETBR activation
CN114423425A (zh) * 2019-07-17 2022-04-29 Enb治疗公司 通过使用内皮素b受体拮抗剂治疗尿路上皮癌和肾癌
TW202120486A (zh) * 2019-08-09 2021-06-01 英商阿帝歐斯製藥有限公司 新穎化合物
EP4608447A1 (en) * 2022-10-28 2025-09-03 ENB Therapeutics, Inc. Methods for treating cancers associated with etbr activation

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090005394A1 (en) * 2007-01-12 2009-01-01 Harbeson Scott L Endothelin receptor antagonists
US20170035836A1 (en) * 2015-08-03 2017-02-09 Enb Therapeutics, Llc Compositions and methods for treating cancers associated with etbr activation

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4874780A (en) * 1987-03-11 1989-10-17 Norsk Hydro A.S. Anticancer compounds
US5496928A (en) 1990-06-07 1996-03-05 Banyu Pharmaceutical Co., Ltd. Endothelin antagonistic substance
TW217417B (https=) 1991-12-04 1993-12-11 Manyu Seiyaku Kk
EP0991660B8 (en) 1997-10-08 2006-04-05 Isotechnika,Inc. DEUTERATED and undeuterated CYCLOSPORINE ANALOGS AND THEIR USE AS IMMUNOMODULATING AGENTS
US7566452B1 (en) 1999-05-04 2009-07-28 New York University Cancer treatment with endothelin receptor antagonists
US6545048B1 (en) 1999-06-29 2003-04-08 California Institute Of Technology Compositions and methods of treating cancer using compositions comprising an inhibitor or endothelin receptor activity
GB0223854D0 (en) 2002-10-12 2002-11-20 Astrazeneca Ab Therapeutic treatment
JP2006508086A (ja) 2002-10-24 2006-03-09 ザ ボード オブ トラスティーズ オブ ザ ユニバーシティ オブ イリノイ 固形腫瘍を予防および治療するための方法および組成物
US7713440B2 (en) 2003-10-08 2010-05-11 Lyotropic Therapeutics, Inc. Stabilized uncoated particles of reversed liquid crystalline phase materials
WO2006019637A2 (en) 2004-07-07 2006-02-23 The Regents Of The University An intelligent nanomedicine integrating diagnosis and therapy
US20080102451A1 (en) 2006-10-31 2008-05-01 Abbott Laboratories Companion diagnostic assays for endothelin receptor antagonists
US9289426B2 (en) 2007-03-21 2016-03-22 University Of Pennsylvania Methods and compositions for treating solid tumors and enhancing tumor vaccines
US8303974B2 (en) 2007-06-11 2012-11-06 Edge Therapeutics, Inc. Drug delivery system for the prevention of cerebral vasospasm
CN102170908A (zh) 2008-08-29 2011-08-31 莱顿大学医学中心附属莱顿教学医院 向个体的肿瘤引流淋巴结递送cd40激动剂
US20110053968A1 (en) * 2009-06-09 2011-03-03 Auspex Pharmaceuticals, Inc. Aminopyrimidine inhibitors of tyrosine kinase
ES2543280T3 (es) 2009-08-10 2015-08-17 Board Of Regents, The University Of Texas System Tratamiento de metástasis cerebrales con inhibidores de los receptores de endotelina en combinación con un agente quimioterapéutico citotóxico
US20140341916A1 (en) 2011-10-28 2014-11-20 Genentech, Inc. Therapeutic combinations and methods of treating melanoma
TWI613215B (zh) 2012-02-22 2018-02-01 再生元醫藥公司 抗－大－內皮素－１（ｂｉｇ－ｅｔ－１）抗體及其用途
US10233277B2 (en) 2012-03-02 2019-03-19 The Governing Council Of The University Of Toronto Polymeric nanoparticles useful in theranostics
WO2014025837A1 (en) 2012-08-06 2014-02-13 Board Of Regents, The University Of Texas System Methods for treatment and prevention of tauopathies by inhibiting endothelin receptors
WO2015095404A2 (en) 2013-12-17 2015-06-25 Genentech, Inc. Methods of treating cancers using pd-1 axis binding antagonists and taxanes
AU2014364606A1 (en) 2013-12-17 2016-07-07 Genentech, Inc. Combination therapy comprising OX40 binding agonists and PD-1 axis binding antagonists
WO2015110593A1 (en) 2014-01-24 2015-07-30 Cecilia Naucler Use of endothelial receptor b inhibitors in prevention and treatment of human cytomegalovirus infection and cmv-related pathologies such as cardiovascular diseases and cancer
US9463201B2 (en) 2014-10-19 2016-10-11 M.G. Therapeutics Ltd Compositions and methods for the treatment of meibomian gland dysfunction
RS61152B2 (sr) 2015-05-12 2024-06-28 Hoffmann La Roche Terapeutski i dijagnostički postupci za lečenje raka
EP3763827A1 (en) 2015-05-29 2021-01-13 F. Hoffmann-La Roche AG Pd-l1 promoter methylation in cancer
JP7144935B2 (ja) 2015-05-29 2022-09-30 ジェネンテック， インコーポレイテッド 癌のための治療方法及び診断方法
JP6821693B2 (ja) 2016-02-29 2021-01-27 ジェネンテック， インコーポレイテッド がんのための治療方法及び診断方法
WO2017165491A1 (en) * 2016-03-24 2017-09-28 Millennium Pharmaceuticals, Inc. Use of a pd-1 antagonist and a raf inhibitor in the treatment of cancer
AU2019206652B2 (en) 2018-01-12 2024-11-14 Enb Therapeutics, Inc. Deuterated compounds, compositions, and methods for treating cancers associated with ETBR activation
EP3746110A4 (en) 2018-03-30 2022-03-02 ENB Therapeutics, Inc. ETBR ANTAGONIST COMPOUNDS, COMPOSITIONS AND USES
CN114423425A (zh) 2019-07-17 2022-04-29 Enb治疗公司 通过使用内皮素b受体拮抗剂治疗尿路上皮癌和肾癌
US20200289495A1 (en) 2020-03-24 2020-09-17 Enb Therapeutics, Inc. Methods of inhibiting endothelin b receptor expressing tumor metastases
US20200268829A1 (en) 2020-03-24 2020-08-27 Enb Therapeutics, Inc. Methods and compositions for inhibiting metastases of an endothelin b receptor expressing cancer

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090005394A1 (en) * 2007-01-12 2009-01-01 Harbeson Scott L Endothelin receptor antagonists
US20170035836A1 (en) * 2015-08-03 2017-02-09 Enb Therapeutics, Llc Compositions and methods for treating cancers associated with etbr activation

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
K,ISHIKAWA 等: "Biochemical and pharmacological profile of a potent and selective", 《PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA》 *

Also Published As

Publication number Publication date
US20190218251A1 (en) 2019-07-18
US12077604B2 (en) 2024-09-03
JP2021510680A (ja) 2021-04-30
JP7539151B2 (ja) 2024-08-23
US20190345197A1 (en) 2019-11-14
KR102846292B1 (ko) 2025-08-13
US11066442B2 (en) 2021-07-20
MX2020007293A (es) 2021-01-08
EP3713571A1 (en) 2020-09-30
WO2019140324A1 (en) 2019-07-18
CA3087009A1 (en) 2019-07-18
US10435434B2 (en) 2019-10-08
US20240360173A1 (en) 2024-10-31
US20210309694A1 (en) 2021-10-07
EA202091630A1 (ru) 2020-12-04
KR20200119246A (ko) 2020-10-19
AU2019206652A1 (en) 2020-07-16
EP3713571A4 (en) 2021-08-25
AU2019206652B2 (en) 2024-11-14

Similar Documents

Publication Publication Date Title
AU2024205010B2 (en) CSF1R inhibitors for use in treating cancer
US12077604B2 (en) Deuterated compounds, compositions, and methods for treating cancers associated with ETBR activation
WO2017024032A2 (en) Compositions and methods for treating cancers associated with etbr activation
US20210077562A1 (en) Etbr antagonist compounds, compositions, and uses
US20220265628A1 (en) Treatment of urothelial and kidney cancers by use of endothelin b receptor antagonists
US20210275518A1 (en) Methods of using rebastinib in the treatment of disorders
EA046650B1 (ru) Дейтерированные соединения, композиции и способы для лечения рака, связанного с активацией etbr

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination